This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Study of TLK199 Tablets in Myelodysplastic Syndrome (MDS)

This study has been completed.
Information provided by (Responsible Party):
Telik Identifier:
First received: January 19, 2006
Last updated: May 30, 2012
Last verified: June 2011
The purpose of this study is to determine the safety and efficacy of TLK199 Tablets in patients with Myelodysplastic Syndrome (MDS)

Condition Intervention Phase
Myelodysplastic Syndrome (MDS) Drug: Ezatiostat Hydrochlorine Phase 1 Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase 1-2a Dose-Ranging Study of TLK199 Tablets in Myelodysplastic Syndrome (MDS)

Resource links provided by NLM:

Further study details as provided by Telik:

Primary Outcome Measures:
  • Maximum Tolerated Dose or Optimal Biologic Dose [ Time Frame: 6 months ]

Secondary Outcome Measures:
  • Safety Pharmacokinetic Parameters, Hematologic Response Parameters [ Time Frame: 6 months ]

Enrollment: 49
Study Start Date: February 2006
Study Completion Date: June 2008
Primary Completion Date: March 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
Dose Escalation Study of TLK199 Tablets From 200 mg Per day To 6000 mg Per Day
Drug: Ezatiostat Hydrochlorine
Oral Tablets in 2 Divided Doses, Dose Escalation From 200 mg Per Day to 6000 mg Per Day on Days 1-7 of each 21 Day Cycle.
Other Names:
  • TLK199 Tablets
  • Telintra

Detailed Description:
This Phase 1-2a study is an open label, dose‑ranging study of TLK199 Tablets in patients with all World Health Organization or French‑American‑British classification types of myelodysplastic syndrome (MDS). In Phase 1, the safety, pharmacokinetics, and hematologic response rate with TLK199 Tablets will be evaluated. The Phase 1 dose‑ranging stage is designed to determine the maximum tolerated dose or optimal biologic dose of TLK199 Tablets. Evaluation of the pharmacokinetics of TLK199 Tablets will be conducted. In Phase 1, an additional 12 patients will undergo pharmacokinetic evaluation under fed conditions at the selected Phase 2a dose. In Phase 2a, further safety and hematologic responses by the modified International Working Group MDS response criteria will be studied.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Histologically confirmed diagnosis of MDS
  • Documented significant cytopenia for at least 2 months
  • Adequate liver and kidney function
  • Ineligible for stem cell bone marrow transplantation
  • At least 18 years of age
  • Discontinuation of growth factors (e.g., G-CSF) within 3 weeks of study entry

Exclusion Criteria:

  • Prior bone marrow transplant
  • Failure to recover from any prior surgery or any major surgery within 4 weeks of study entry
  • Pregnant or lactating women
  • Other investigational drugs within 14 days of study entry
  • Chemotherapy, radiotherapy or immunotherapy within 14 days of study entry
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00280631

United States, Illinois
Loyola University Chicago-Cardinal Bernardin Cancer Center
Maywood, Illinois, United States, 60153
Loyola University Medical Center
Maywood, Illinois, United States, 60153
United States, Massachusetts
University of Massachusetts (UMass) Memorial Medical Center
Worcester, Massachusetts, United States, 01655
Sponsors and Collaborators
Study Director: Gail Brown, MD Telik
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Telik Identifier: NCT00280631     History of Changes
Other Study ID Numbers: TLK199.1101
Study First Received: January 19, 2006
Last Updated: May 30, 2012

Additional relevant MeSH terms:
Myelodysplastic Syndromes
Pathologic Processes
Bone Marrow Diseases
Hematologic Diseases
Precancerous Conditions
Neoplasms processed this record on September 21, 2017